Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Persistence of Hepatitis B Antibodies, Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine, Engerix™-B Kinder (SKF103860) Challenge Dose, in Adolescents Vaccinated With Four Doses of Infanrix™ Hexa (SB217744) During Infancy

NCT02798952 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT02798952
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02798952 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Persistence of Hepatitis B Antibodies, Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine, Engerix™-B Kinder (SKF103860) Challenge Dose, in Adolescents Vaccinated With Four Doses of Infanrix™ Hexa (SB217744) During Infancy
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
August 23, 2016
Completion date
July 5, 2017
Enrollment
302 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b